Immunovant, the poster child for the hot new biotech flotation vehicle, might soon go private again.
The clock is ticking for the flood of blank-cheque companies that raised money last year, and competition is only getting hotter.
Immunovant and other FcRn-players must hope that a potential safety signal turns out to be indication rather than class specific.
Early 2021 will see rare diseases dominate for biotech, with Sarepta revealing key data on its gene therapy play.
A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.
Formation of Spacs – special-purpose acquisition companies – is surging, but will fierce competition for deals hurt performance?
The $6.5bn price – biopharma’s biggest buyout of the year so far – shows how competitive the anti-FcRn space has become.
Crucial clinical data are expected in the third quarter for small to mid-sized players including Beigene, Turning Point, Intra-cellular and Immunovant.